Objective To evaluate the efficacy and toxicity of docetaxel combined with Cisplatin(DDP) and 5-fluorouracil(5-Fu) in the treatment of advanced gastric cancer. Methods 35 patients with advanced gastric cancer,which were confirmed by pathological diagnosis,were treated with docetaxel + DDP +5-Fu regimen:docetaxel 70 mg/m2 iv infusion for 4 hours on day 1, DDP 20 mg/m2 iv infusion on day 1 to 5,5-Fu 750 mg/m2 iv infusion for 6 hours on day 1 to 5 every 3 ～ 4weeks. Patients responsing to the chemotherapy finished at least 4 ～ 6 cycles or proceeded the therapy until progression of the disease (PD). Results 32 cases (91.4% ) were available for response evaluation with CR0;PR 15;SD7;PD 10. The rate of total remission( CR + PR) was 46.9% (15/32) ,and rates of CR and SD were 0 and 21.9% respectively. Leucopenia was seen in 40% patients,in which 13.6% cases were in grade III -IV. One patient had fever with neutropenia and improved after active treatment. There was no systemic infection or therapy-related death in all patients. Conclusion Docetaxel + DDP +5-Fu regimen has an assured response for advanced gastric cancer with tolerable toxicity and could be an effective candidate in clinical treatment.

Objective To explore the effect of the surgical technique of jejunum fistula and conventional indwelling nasogastric tube with total gastrectomy. Methods The clinical data of 23 advanced gastric cancer patients with total gastrectomy were retrospetively analyzed. Among 23 cases, 17 received jejunum fistual and 6 received indwelling nasogastric. The time to flatus and the ratio of postoperative complications including throat ache, nausea,pneumonia, anastomotic leak were compared. Results Compared with A group, the incidence of disadvantage spit sputum, dyssomnia, throat ache and nausea in B group reduced significantly, the time to flatus was advanced in B group. And other postoperative complications had no difference between two groups. Conclusion Jejunum fistula was rational, safe and effective in patients with total gastrectomy

BACKGROUND:Immunity of fetal liver stem cel transplantation is rarely reported, syngeneic and al ogeneic fetal liver stem cel transplantation in the treatment of hepatic cirrhosis is stil unclear.
OBJECTIVE:To observe the therapeutic effects of syngeneic and al ogeneic fetal liver stem cel transplantation on hepatic cirrhosis as wel as immune rejections during the therapeutic process.
METHODS:The fetal liver stem/progenitor cel s from BALB/c and C57BL/6 mice were isolated and purified by the type IV col agen enzyme digestion method. A total of 104 healthy BALB/c mice were randomly assigned to four groups. Normal control group:no treatment;Hepatic cirrhosis group, syngeneic transplantation group and al ogeneic transplantation group:16 weeks after hepatic cirrhosis models of mice were developed by intraperitoneal injection with carbon tetrachloride, physiological saline, syngeneic fetal liver stem cel s and al ogeneic fetal liver stem cel s were injected via the caudal vein. Final y, the survival statuses, liver function, hepatic fibrosis index, the number and ratio of immune cel s (CD4+T, CD8+T, NK, NKT) and histopathologic examinations were compared in each group after transplantation 4 weeks.
RESULTS AND CONCLUSION:The survival rates in the two transplantation groups were both 100%, which was significantly higher than that in the hepatic cirrhosis group (67%, P<0.05). The liver function and liver fibrosis index in each group did not show statistical differences (P>0.05). Immunological tests showed no difference between groups (P>0.05). Pathohistology examination of hepatic tissue repair:Al ogeneic transplantation group>syngeneic transplantation group>hepatic cirrhosis group. Hence, fetal liver stem cel transplantation via the caudal vein could elevate the survival rate of hepatic cirrhosis mice, al eviate the degree of hepatocyte necrosis. There is no immunologic rejection during syngeneic and al ogeneic fetal liver stem cel transplantation that could help to treat hepatic cirrhosis in mice.

Objective To investigate the relationship between concentration change of serum 5‐hydroxy tryptamine and clinical symptoms improvement in primary premature ejaculation with the treatment of paroxitine .Methods 81 cases of lifelong PE and an intra‐vaginal ejaculation latency time (IELT ) ≤60 s were included in this study .Subjects were divided into 2 groups according to the IELT ,group A (IELT≤30 s) and group B (30 s

In this study, we used next-generation sequencing methods to screen 300 individuals for BRCA1 and BRCA2. A novel mutation (c.849dupT) in BRCA2 was identified in a female patient and her unaffected brothers. This mutation leads to the truncation of BRCA2 functional domains. Moreover, BRCA2 mRNA expression levels in mutation carriers are significantly reduced compared to noncarriers. Immunofluorescence and western blot assays showed that this mutation resulted in reduced BRCA2 protein expression. Thus, we identified a novel mutation that damaged the function and expression of BRCA2 in a family with breast cancer history. The pedigree analysis suggested that this mutation is strongly associated with familial breast cancer. Genetic counsellors suggest that mutation carriers in this family undergo routine screening for breast cancer, as well as other malignancies, such as prostate and ovarian cancer. The effects of this BRCA2 mutation on drug resistance should be taken into consideration during treatment.
Blotting, Western ; BRCA2 Protein ; Breast Neoplasms* ; Breast* ; Drug Resistance ; Female ; Fluorescent Antibody Technique ; Genes, BRCA2 ; High-Throughput Nucleotide Sequencing ; Humans ; Mass Screening ; Nonsense Mediated mRNA Decay* ; Ovarian Neoplasms ; Pedigree ; Prostate ; RNA, Messenger ; Siblings